Craig A Erickson
Overview
Explore the profile of Craig A Erickson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
140
Citations
2282
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Norris J, De Stefano L, McKinney W, Schmitt L, Miyakoshi M, Gross C, et al.
medRxiv
. 2025 Feb;
PMID: 39973986
Background: Fragile X Syndrome (FXS) is a rare, neurodevelopmental disorder caused by a mutation to the Fragile X messenger ribonucleoprotein 1 () gene and characterized by sensory processing abnormalities and...
2.
Oberman L, Berry-Kravis E, Budimirovic D, Erickson C, Hagerman R, Harris H, et al.
J Child Adolesc Psychopharmacol
. 2025 Feb;
PMID: 39912805
The current intense period of drug development for fragile X syndrome (FXS) and other neurodevelopmental disorders (NDDs) indications has highlighted the importance of behavioral outcome measures with strong psychometric properties...
3.
Elmaghraby R, Blank E, Miyakoshi M, Gilbert D, Wu S, Larsh T, et al.
J Child Adolesc Psychopharmacol
. 2025 Jan;
PMID: 39792483
Autism spectrum disorder (ASD) is characterized by deficits in social behavior and executive function (EF), particularly in cognitive flexibility. Whether transcranial magnetic stimulation (TMS) can improve cognitive outcomes in patients...
4.
Smith E, Dominick K, Schmitt L, Pedapati E, Erickson C
J Neurodev Disord
. 2024 Dec;
16(1):69.
PMID: 39701935
Specialization of the brain for language is early emerging and essential for language learning in young children. Fragile X Syndrome (FXS) is a neurogenetic disorder marked by high rates of...
5.
Nelson M, Schmitt L, Horn P, Berry-Kravis E, Hessl D, Shaffer R, et al.
J Autism Dev Disord
. 2024 Nov;
PMID: 39579284
Estimating meaningful change thresholds (MCT) on clinical outcome assessments is an important consideration when evaluating treatments. In fragile X syndrome (FXS) research, there has been no consensus on how to...
6.
Protic D, Breeze E, Mendoza G, Zafarullah M, Abbeduto L, Hagerman R, et al.
SAGE Open Med
. 2024 Nov;
12:20503121241282401.
PMID: 39483619
Background: Fragile X syndrome, with an approximate incidence rate of 1 in 4000 males to 1 in 8000 females, is the most prevalent genetic cause of heritable intellectual disability and...
7.
Ammerman R, Erickson C
Pediatr Clin North Am
. 2024 Oct;
71(6):xvii-xix.
PMID: 39433388
No abstract available.
8.
Schmitt L, Nelson M, Shaffer R, Erickson C
Sci Rep
. 2024 Oct;
14(1):23058.
PMID: 39367109
Fragile X Syndrome (FXS) is an X-linked disorder leading to the loss of expression of FMR1-protein product, FMRP. The absence or deficiency of FMRP is thought to result in the...
9.
Ethridge L, Pedapati E, Schmitt L, Norris J, Auger E, De Stefano L, et al.
Sci Rep
. 2024 Oct;
14(1):22982.
PMID: 39362936
Recent failures translating preclinical behavioral treatment effects to positive clinical trial results in humans with Fragile X Syndrome (FXS) support refocusing attention on biological pathways and associated measures, such as...
10.
Erickson C, Perez-Cano L, Pedapati E, Painbeni E, Bonfils G, Schmitt L, et al.
Biomedicines
. 2024 Jul;
12(7).
PMID: 39062003
This study aimed to evaluate the safety and tolerability of STP1, a combination of ibudilast and bumetanide, tailored for the treatment of a clinically and biologically defined subgroup of patients...